Jefferies Global Healthcare Conference
Logotype for Kyverna Therapeutics Inc

Kyverna Therapeutics (KYTX) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Kyverna Therapeutics Inc

Jefferies Global Healthcare Conference summary

19 Nov, 2026

Strategy and platform

  • Miv-cel is designed for potency and improved safety; more than 100 patients treated, with durable drug-free remissions and a manageable, tolerable safety profile reported.

  • The construct is a fully humanized autologous CD19 CAR-T with a CD28 co-stimulatory domain and modified hinge and transmembrane regions; translational findings include CNS penetration and immune-cell changes consistent with an immune reset.

  • Dual-source manufacturing uses ElevateBio and Minaris Advanced Therapies; ElevateBio is the key commercial source, with a reported manufacturing success rate above 98%.

  • Cash runway extends well into 2028, supporting planned development and commercial milestones.

Stiff person syndrome

  • The first BLA for stiff person syndrome and the first BLA for an autoimmune cell therapy worldwide was filed; with RMAT designation, priority review is being sought, with FDA acceptance and a planned PDUFA date update expected in 2027.

  • A commercial launch is planned for 2027; launch preparation is underway, with 10 academic centers targeted as initial focal sites.

  • Timed 25-foot walk improved 46% at week 16 versus a 20% clinically meaningful threshold, and 49% at week 52; both results were described as highly statistically significant.

  • Two-thirds of patients who used a walking aid at baseline no longer needed one by week 16; this improvement continued through week 52. No high-grade CRS or ICANS, or reported IEC-HS, was reported; three treatment-related serious AEs resolved during the study.

  • The U.S. population includes 6,000 diagnosed patients, with 2,000–2,500 refractory to IVIG and other immunosuppressants; the targeted launch population was described as a multi-billion-dollar opportunity.

Generalized myasthenia gravis

  • Phase II results showed week-24 reductions of 8.3 in MG-ADL and 11.7 in QMG, with durable improvements extending to one year and beyond; meaningful clinical impact across key endpoints was reported in all patients.

  • A randomized, controlled pivotal Phase III study versus standard of care is enrolling; enrollment is expected to finish in mid-2027.

  • No high-grade CRS or ICANS, or reported IEC-HS, was observed in the study population; no severe adverse events of any grade were reported.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Kyverna Therapeutics